Patent US4639439A successfully refreshed from Google Patents.
US4639439A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Contraceptive composition
Assignee: Societe dEtudes Scientifiques et Industrielles de lIle de France SA
•
Filing: 1985-10-10
•
Granted: 1987-01-27
•
Expires: 2005-10-10
Abstract
Abstract The invention relates to a contraceptive composition of a prolactin elevag benzamide, such as N-[(1-ethyl-2-pyrrolidinyl)methyl]2-methoxy 5-sulfamoyl benzamide, and a progestogen.
Inventors
- 👤 Peter W. Howie
- 👤 Alan McNeilly
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 17:19
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/565
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
18 words
A pharmaceutical composition for suppressing fertility comprising a prolactin elevating benzamide, a progestogen and a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
18 words
A pharmaceutical composition for suppressing fertility comprising a prolactin elevating benzamide, a progestogen and a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
10 words
The composition of claim 1 wherein the benzamide is sulpiride.
Claim 4
Dependent Claim
21 words
The composition of claim 2 in which sulpiride is employed in amounts from about 5 to 25 mg per unit dose.
Claim 5
Dependent Claim
11 words
The composition of claim 1 in which the progestogen is norethindrone.
Claim 6
Dependent Claim
18 words
The composition of claim 4 in which the norethindrone is employed in amounts from 5 to 250 micrograms.
Claim 7
Dependent Claim
11 words
The composition of claim 1 in which the progestogen is lynestrenol.
Claim 8
Dependent Claim
8 words
The composition of claim 1 including an estrogen.
Claim 9
Dependent Claim
11 words
The composition of claim 7 in which the estrogen is ethinyl-estradiol.
Claim 10
Dependent Claim
36 words
Process for treating a subject to inhibit ovulation prior to commencement of progestogenic contraception comprising administering a therapeutically effective dosage of a pharmaceutical composition comprising a prolactin elevating benzamide, a progestogen and a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
36 words
Process for treating a subject to inhibit ovulation prior to commencement of progestogenic contraception comprising administering a therapeutically effective dosage of a pharmaceutical composition comprising a prolactin elevating benzamide, a progestogen and a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
32 words
Process for suppressing fertility without inhibiting lactation by administering to a subject a therapeutically effective dosage of a contraceptive composition comprising a prolactin elevating benzamide, a progestogen and a pharmaceutically acceptable carrier.
Claim 13
Dependent Claim
32 words
Process for suppressing fertility without inhibiting lactation by administering to a subject a therapeutically effective dosage of a contraceptive composition comprising a prolactin elevating benzamide, a progestogen and a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
US4067975A
Cited
US4512987A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-01-26 | 1990-07-28 | 1991-01-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-01-26 | 1994-07-28 | 1995-01-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-01-26 | 1998-07-28 | 1999-01-27 | $7700.00 | Window Closed / Lapsed |